Standard treatment for postmenopausal breast cancer is to give a hormonal (endocrine) breast cancer drug for 5 years following surgical removal of the tumour. The results of the recent study (ABCSG 16/S.A.L.S.A) conducted by the Austrian Breast & Colorectal Cancer Study Group (ABCSG) now show that two years of follow-on treatment with the aromatase inhibitor anastrozole is sufficient.
Gliomas are a type of brain tumour characterised by a poor prognosis. In order to improve this prognosis, as much of the tumour as possible must be removed safely during the neurosurgical operation. However, especially in the case of slow-growing, low-grade gliomas, it is often difficult to distinguish diseased tissue from healthy tissue. In a joint project, MedUni Vienna, the University of California in San Francisco and the Dartmouth-Hitchcock Medical Center (both USA) have now trialed a technique designed to make low-grade gliomas visible. The technique involved using an innovative probe together with 5-ALA as a fluorescence marker during the operation. 5-ALA fluorescence specialist Georg Widhalm, Department of Neurosurgery and member MedUni Vienna/Vienna General Hospital Comprehensive Cancer Center was heavily involved in the project.
MFPL group leaders Claudine Kraft (University of Vienna) and Alwin Köhler (Medical University of Vienna) are each awarded a prestigious ERC Consolidator Grant. One of the most meaningful awards for researchers in Europe, the ERC Consolidator Grant will support their research in recognition of their future potential and past achievements. The funding amounts to EUR 2.000.000 over the course of five years for each grant.
WSA Young Innovators is a special recognition for young social entrepreneurs under 30 years of age, using ICTs to take action on the United Nations Sustainable Development Goals (UN SDGs). Together with the WSA winners of each year, they are honored as outstanding digital innovation with social impact.
The food allergy, which is related to birch pollen, is a very common attendant phenomenon associated with birch pollen allergy – indeed around 70% of those with a birch pollen allergy are also allergic to apples. That amounts to around 280,000 people in Austria. In those affected, eating apples leads to swelling and rashes or itching in the mouth and gullet, as well as in the ear area, and even to blistering. Working in close collaboration with Tamar Kinaciyan at MedUni Vienna's Department of Dermatology, a research group led by Barbara Bohle at the Institute of Pathophysiology and Allergy Research has now proven in a Phase II trial that the apple allergen "Mal d 1" significantly reduces the symptoms of apple allergy and is therefore an effective and safe treatment option.